Cargando…

Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells

The cellular internalization of drug carriers occurs via different endocytic pathways that ultimately involve the endosomes and the lysosomes, organelles where the pH value drops to 6.0 and 5.0, respectively. We aimed to design and characterize pH/temperature-responsive carriers for the effective de...

Descripción completa

Detalles Bibliográficos
Autores principales: Fundueanu, Gheorghe, Constantin, Marieta, Turtoi, Mihaela, Bucatariu, Sanda-Maria, Cosman, Bogdan, Anghelache, Maria, Voicu, Geanina, Calin, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026771/
https://www.ncbi.nlm.nih.gov/pubmed/35456699
http://dx.doi.org/10.3390/pharmaceutics14040865
_version_ 1784691193581404160
author Fundueanu, Gheorghe
Constantin, Marieta
Turtoi, Mihaela
Bucatariu, Sanda-Maria
Cosman, Bogdan
Anghelache, Maria
Voicu, Geanina
Calin, Manuela
author_facet Fundueanu, Gheorghe
Constantin, Marieta
Turtoi, Mihaela
Bucatariu, Sanda-Maria
Cosman, Bogdan
Anghelache, Maria
Voicu, Geanina
Calin, Manuela
author_sort Fundueanu, Gheorghe
collection PubMed
description The cellular internalization of drug carriers occurs via different endocytic pathways that ultimately involve the endosomes and the lysosomes, organelles where the pH value drops to 6.0 and 5.0, respectively. We aimed to design and characterize pH/temperature-responsive carriers for the effective delivery of the anti-tumoral drug doxorubicin. To this purpose, poly(N-isopropylacrylamide-co-vinylimidazole) was synthesized as an attractive pH/temperature-sensitive copolymer. Microspheres made of this copolymer, loaded with doxorubicin (MS-DXR), disintegrate in monodisperse nanospheres (NS-DXR) under conditions similar to that found in the bloodstream (pH = 7.4, temperature of 36 °C) releasing a small amount of payload. However, in environments that simulate the endosomal and lysosomal conditions, nanospheres solubilize, releasing the entire amount of drug. We followed the NS-DXR internalization using two cancer cell lines, hepatic carcinoma HepG2 cells and lung adenocarcinoma A549 cells. The data showed that NS-DXR are internalized to a greater extent by HepG2 cells than A549 cells, and this correlated with increased cytotoxicity induced by NS-DXR in HepG2 cells compared with A549 cells. Moreover, NS-DXR particles do not cause hemolysis and erythrocytes aggregation. Administered in vivo, NS-DXR localized in the liver and kidneys of mice, and the loading of DXR into NS resulted in the reduced renal clearance of DXR. In conclusion, the newly developed poly(N-isopropylacrylamide-co-vinyl imidazole) particles are biocompatible and may be introduced as carriers for doxorubicin to hepatic tumors.
format Online
Article
Text
id pubmed-9026771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90267712022-04-23 Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells Fundueanu, Gheorghe Constantin, Marieta Turtoi, Mihaela Bucatariu, Sanda-Maria Cosman, Bogdan Anghelache, Maria Voicu, Geanina Calin, Manuela Pharmaceutics Article The cellular internalization of drug carriers occurs via different endocytic pathways that ultimately involve the endosomes and the lysosomes, organelles where the pH value drops to 6.0 and 5.0, respectively. We aimed to design and characterize pH/temperature-responsive carriers for the effective delivery of the anti-tumoral drug doxorubicin. To this purpose, poly(N-isopropylacrylamide-co-vinylimidazole) was synthesized as an attractive pH/temperature-sensitive copolymer. Microspheres made of this copolymer, loaded with doxorubicin (MS-DXR), disintegrate in monodisperse nanospheres (NS-DXR) under conditions similar to that found in the bloodstream (pH = 7.4, temperature of 36 °C) releasing a small amount of payload. However, in environments that simulate the endosomal and lysosomal conditions, nanospheres solubilize, releasing the entire amount of drug. We followed the NS-DXR internalization using two cancer cell lines, hepatic carcinoma HepG2 cells and lung adenocarcinoma A549 cells. The data showed that NS-DXR are internalized to a greater extent by HepG2 cells than A549 cells, and this correlated with increased cytotoxicity induced by NS-DXR in HepG2 cells compared with A549 cells. Moreover, NS-DXR particles do not cause hemolysis and erythrocytes aggregation. Administered in vivo, NS-DXR localized in the liver and kidneys of mice, and the loading of DXR into NS resulted in the reduced renal clearance of DXR. In conclusion, the newly developed poly(N-isopropylacrylamide-co-vinyl imidazole) particles are biocompatible and may be introduced as carriers for doxorubicin to hepatic tumors. MDPI 2022-04-15 /pmc/articles/PMC9026771/ /pubmed/35456699 http://dx.doi.org/10.3390/pharmaceutics14040865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fundueanu, Gheorghe
Constantin, Marieta
Turtoi, Mihaela
Bucatariu, Sanda-Maria
Cosman, Bogdan
Anghelache, Maria
Voicu, Geanina
Calin, Manuela
Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title_full Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title_fullStr Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title_full_unstemmed Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title_short Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
title_sort bio-responsive carriers for controlled delivery of doxorubicin to cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026771/
https://www.ncbi.nlm.nih.gov/pubmed/35456699
http://dx.doi.org/10.3390/pharmaceutics14040865
work_keys_str_mv AT fundueanugheorghe bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT constantinmarieta bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT turtoimihaela bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT bucatariusandamaria bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT cosmanbogdan bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT anghelachemaria bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT voicugeanina bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells
AT calinmanuela bioresponsivecarriersforcontrolleddeliveryofdoxorubicintocancercells